Analysis of functional changes under using of candesartan cilexetil with resveratrol in animals

A. Beliayeva, L. Garmanchuk
Taras Shevchenko National University of Kyiv, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv

Abstract


Cardiovascular diseases are widespread throughout the world. The incidence of diseases of the cardiovascular system has increased several times. Cardiovascular diseases have become the leading cause of death in many countries. Currently, the efforts of many researchers are aimed at studying and creating new, more effective and safe drugs and their combinations for the treatment of pathology of the cardiovascular system. Candesartan cilexetil is an angiotensin II receptor antagonist. It is used medicinally as a long-acting antihypertensive agent. However, this drug has a number of side effects. Resveratrol is a natural antioxidant. This substance exhibits pleiotropic effects, including antioxidant, anti-inflammatory, anti-aging, cardioprotective, and neuroprotective activities. The aim is investigation of acute toxicity of candesartan cilexetil and resveratrol in combination in vivo. Male and female ICR mice were used for the experiment. Animals received candesartan cilexetil and resveratrol intragastrically once. Evaluation of
the effects of substances on internal organs (heart, spleen, kidneys, lungs, liver and brain) was carried out in 2 weeks after the introduction of the substances. It was shown that candesartan cilexetil with natural resveratrol did not lead to functional changes. There were no changes of behavior during the observation period. The combination of candesartan cilexetil with resveratrol did not lead to the death of mice, therefore the mean lethal dose (LD50) was not determined. The new combination of substances was safe. No side effects have been reported. The combination of candesartan cilexetil with resveratrol is non-toxic, and the use of these substances is safe for animals.

Keywords


Cardiovascular diseases, candesartan cilexetil, resveratrol, acute toxicity

Full Text:

PDF>PDF

References


Zhao D, Liu H, Dong P. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. Clin Exp Hypertens 2019;41(1):75-79.

De Rosa ML, Chiariello M. Candesartan improves maximal exercise capacity in hypertensives results of a randomized placebo-controlled crossover trial. J. Clin Hypertens. 2009; 11 (4): 192–200.

Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Europ J of Pharmacology. 1998; 354 (2/3): 179–187.

Adi Y. Berman, Rachel A. Motechin, Maia Y. Wiesenfeld, Marina K. Holz. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017; 1: 35.

Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab. 2009 Jul; 10(6): 530-46.

Riba A., Deres L., Sumegi B., Toth K., Szabados E., Halmosi R. Cardioprotective effect of resveratrol in a postinfarction heart failure model. Oxid. Med. Cell. Longev. 2017;2017:6819281. doi: 10.1155/2017/6819281.

Zhigang Zhang, Li Gao, Yanyan Cheng, Jing Jiang, Yan Chen, Huijie Jiang, Hongxiang Yu, Anshan Shan, Baojing Cheng. Resveratrol, a Natural Antioxidant, Has a Protective Effect on Liver Injury Induced by Inorganic Arsenic Exposure. BioMed Research International. Volume 2014, Article ID 617202, 7 pages. http://dx.doi.org/10.1155/2014/617202.

Beliayeva A., Garmanchuk L. Changing in the number of CD117+ stem cells, cytogenetic and cytokinetic parameters under the using of candesartan, candesartan cilexetil and resveratrol in vitro. Visnyk Taras Shevchenko National University of Kyiv. 2019; 3(79): 54 – 57.

Р. У. Хабриев. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. 2-е изд., перераб. и доп. Медицина, 2005; 832 с.

Г. Н. Шилов, А. И. Хоменко, В. В. Евстигнеев. Основы разработки новых лекарственных средств. Мед. новости. 2009; № 2: 23–28.

Received: 05.01.2021

Revised: 01.02.2021

Signed for the press: 01.02.2021




DOI: http://dx.doi.org/10.17721/1728_2748.2021.84.24-27

Refbacks

  • There are currently no refbacks.


Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).